Radiology Groups Push Back on New Cancer Screening Guidelines - Report - MDSpire

Radiology Groups Push Back on New Cancer Screening Guidelines

Radiology groups say the ACP's new screening recommendations conflict with nearly every major cancer organization and could cost thousands of lives annually.

  • By

  • Kerri Miller

  • April 17, 2026

  • 2 min

Share

Clinical Report: Radiology Groups Push Back on New Cancer Screening Guidelines

Overview

The American College of Radiology and Society of Breast Imaging have criticized the American College of Physicians' updated breast cancer screening guidelines, claiming they could lead to increased mortality. They advocate for annual screenings starting at age 40, aligning with other major cancer organizations.

Background

Breast cancer screening is a critical component of preventive healthcare, as early detection can significantly reduce mortality rates. Recent updates to screening guidelines have sparked debate among healthcare professionals regarding the optimal age and frequency for screenings. The implications of these guidelines are profound, potentially affecting thousands of lives annually.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • The ACP recommends biennial screening for women aged 50 to 74, which the ACR and SBI argue is outdated.
  • ACR and SBI estimate that the ACP's guidelines could result in an additional 10,000 breast cancer deaths annually in the US.
  • They advocate for annual screenings starting at age 40, supported by multiple cancer organizations.
  • The ACR and SBI dispute the ACP's claims regarding screening harms, citing a 40% drop in breast cancer death rates since the 1980s.
  • The ACP's guidance applies only to average-risk, asymptomatic patients.

Clinical Implications

Clinicians should be aware of the differing recommendations regarding breast cancer screening and consider the potential consequences of adhering to the ACP's guidelines. Ongoing discussions and research are essential to ensure that screening practices align with the best available evidence and patient outcomes.

Conclusion

The debate over breast cancer screening guidelines highlights the need for continuous evaluation of clinical practices to optimize patient care. Collaboration among various medical organizations is crucial to establish consensus on effective screening strategies.

References

  1. The ASCO Post, 2012 -- As Conflicting Guidelines Evolve, Experts Continue to Debate the Merits of Cancer Screening
  2. The ASCO Post, 2025 -- Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
  3. The ASCO, 2014 -- Time to Move Forward With Lung Screening
  4. The ASCO Post, 2014 -- Decision Time for Lung Cancer Screening in High‑Risk Populations

Original Source(s)

Radiology Groups Push Back on New Cancer Screening Guidelines

  • by Kerri Miller

  • April 17, 2026

Related Content

Trauma CT and Unexpected Findings

Investigators evaluate classification of incidental findings on trauma whole-body CT.

FDA Cleared ≠ FDA Validated

Most AI medical devices reach the market without independent evidence of safety or effectiveness.

Most Salivary Gland Neoplasms Found to Be Benign in Single-Center Study

Analysis of 50 cases shows moderate diagnostic agreement between FNAC and histopathology and identifies pleomorphic adenoma as the most common neoplasm.